Zachary Klaassen
Articles
-
Oct 15, 2024 |
urotoday.com | Zachary Klaassen
Read the Full Video TranscriptPhillip Koo: Hi, this is Phillip Koo. I'm joined today by Dr. Zach Klaassen from Wellstar MCG Health. Today we're going to talk about the sequential lutetium-177 PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer. This is the UpFrontPSMA study that was recently presented at ESMO 2024. So here's the study.
-
Sep 6, 2024 |
urotoday.com | Zachary Klaassen
Read the Full Video TranscriptRashid Sayyid: Hello, everyone, and thank you for joining us today in this UroToday recording. I'm Rashid Sayyid, robotic urology and oncology fellow at USC, and I'm joined today by Zach Klaassen, associate professor and program director at Wellstar MCG Health. We'll be discussing the 2024 key updates to the NCCN prostate cancer guidelines that were published in March of 2024.
-
Aug 23, 2024 |
urotoday.com | Zachary Klaassen
Read the Full Video TranscriptRashid Sayyid: Hello, everyone, and thank you for joining us today in this UroToday Journal Club recording. I'm Rashid Sayyid, a robotic urologic oncology fellow at USC, and I'm delighted to be joined today by Zach Klaassen, associate professor and program director at WellStar MCG Health. We'll be discussing the recently published JAMA Oncology meta-analysis looking at cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer.
-
Jul 26, 2024 |
urotoday.com | Zachary Klaassen
Rashid Sayyid and Zach Klaassen review the 2024 NCCN prostate cancer guideline updates focusing on treatment-related bone loss in patients on androgen deprivation therapy (ADT). They emphasize the importance of addressing bone health due to increased fracture risk associated with ADT. The speakers outline a comprehensive approach to bone health management, including risk assessment using the FRAX tool, DEXA scans, lifestyle modifications, and calcium and vitamin D supplementation.
-
Jul 25, 2024 |
urotoday.com | Zachary Klaassen
Read the Full Video TranscriptRashid Sayyid: Hello everyone, and thank you for joining us today in this UroToday recording. I'm Rashid Sayyid, a urological oncology fellow at the University of Toronto, and I'm joined today by Zach Klaassen, associate professor and program director at Wellstar MCG Health, where we'll be going over the 2024 key updates to the NCCN prostate cancer guidelines.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →